09:34 AM EST - Odyssey Group International Inc : Presented at the Military Health System Research Symposium. Odyssey is developing a novel pharmaceutical, ONP-002, to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury also known as a concussion. MHSRS requested presentation submissions and after review, selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference. Odyssey Group International Inc
shares O.ODYY are trading unchanged at $0.08.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ODYY&qmodStoryID=5622906098310252
